umifenovir has been researched along with ritonavir in 44 studies
| Studies (umifenovir) | Trials (umifenovir) | Recent Studies (post-2010) (umifenovir) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 234 | 23 | 172 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | umifenovir (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 44 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, F; Chen, X; Lu, Y; Wang, Z; Zhang, W | 1 |
| Deng, L; Hong, Z; Li, C; Li, X; Liu, X; Xia, J; Zeng, Q; Zhang, H | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Chen, C; Lu, J; Lu, Z; Xu, T; Xue, Y; Yang, G; Zha, T; Zhu, Z | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Jiang, J; Lin, S; Ruan, J; Wang, L; Xu, X; Ye, H | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Jiang, Y; Liu, H; Xie, X; Zeng, Y | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Cai, C; Deng, Y; Hu, ZY; Huang, K; Huang, Y; Wang, X; Wang, Y; Xie, J; Xie, Y; Xu, D; Zang, J; Zhan, T; Zheng, F | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| Cleland, E; Giovane, RA; Henderson, CE; Rezai, S | 1 |
| Cai, J; Lang, G; Ni, Q; Shen, X; Sheng, J; Su, J; Wu, W; Xu, K; Zhao, H; Zhu, B | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Cui, M; Guo, Y; Hong, P; Hou, Z; Liu, F; Lu, Y; Qian, X; Qiu, F; Song, P; Tong, G; Wan, D; Wang, N; Wang, S; Wang, X; Xu, Y; Yu, H; Zhan, Y; Zheng, Z; Zhu, L; Zou, X | 1 |
| Al-Yamani, MJ; Asdaq, SMB; Jomah, S | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Cai, W; Chen, X; Deng, X; Guan, Y; Hong, W; Hu, F; Li, F; Li, L; Li, Y; Lin, W; Liu, J; Mo, X; Peng, P; Wang, J; Wang, Y; Wen, C; Xiao, G; Xie, Z; Zhang, F; Zhang, L | 1 |
| Guo, F; Li, S; Liu, C; Shang, D; Taleb, SJ; Tong, M | 1 |
| Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X | 1 |
| Deng, M; Hu, Y; Jiang, L; Luo, X; Pan, L; Wang, M; Wu, T; Xia, Z; Yang, X; You, Y; Zuo, Z | 1 |
| Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ | 1 |
| Cui, X; Friedemann, T; Geng, Z; Ling, Y; Lu, H; Lu, Y; Lv, Y; Schröder, S; Shi, Y; Su, J; Tao, Z; Xia, L; Zhao, R | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Chen, X; Huang, Z; Kuang, Y; Liu, C; Liu, P; Pan, P; Yin, M | 1 |
| Dehghan, N; Keyvani, H; Laali, A; Makiani, MJ; Navaei, M; Nojomi, M; Ranjbar, M; Roham, M; Yassin, Z | 1 |
| Gao, Q; Liu, D; Ma, D; Song, C; Tan, J; Xu, C; Yuan, Y | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Chen, J; Liu, D; Lu, H; Yin, L; Zhang, L | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Cai, H; Dai, W; Fang, Q; Guo, Y; Lang, G; Li, L; Li, Y; Liu, J; Ni, Q; Qiu, Y; Shi, D; Su, J; Tao, J; Wang, X; Wu, W; Wu, X; Xia, Q; Xu, K; Xu, M; Xu, Y; Yi, P; Yu, L; Zhao, H; Zhou, J | 1 |
| Chen, Y; Fan, L; Gu, Y; Li, N; Liu, C; Liu, H; Liu, Y | 1 |
| Lan, X; Shao, C; Wu, Z; Xu, Y; Zeng, X | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Chen, G; Ding, T; Hong, Z; Li, X; Liang, S; Liu, X; Shang, Y; Wei, L; Wu, M; Xia, J; Zou, Z | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Bao, Y; Chen, Z; Ding, J; Feng, Y; Guan, H; Li, H; Liu, W; Wang, X; Zhou, Z | 1 |
| Hu, Y; Jiang, S; Li, L; Lu, X; Wang, R; Wang, X; Zuo, M | 1 |
| Alavi Darazam, I; Amirdosara, M; Dehbsneh, HS; Gachkar, L; Gharehbagh, FJ; Hajiesmaeili, M; Hatami, F; Irvani, SSN; Khalili, N; Khoshkar, A; Kusha, AH; Lotfollahi, L; Mardani, M; Moradi, O; Pourhoseingholi, MA; Rabiei, MM; Rezaei, O; Shabani, M; Shokouhi, S; Shoushtari, MT; Soleymaninia, A; Torabinavid, P | 1 |
| Huang, LY; Lei, YH; Li, S; Wang, DC; Wei, J; Yu, M | 1 |
20 review(s) available for umifenovir and ritonavir
| Article | Year |
|---|---|
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Drug Combinations; Drug Repositioning; Esters; Gabexate; Gene Expression Regulation; Guanidines; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Janus Kinase Inhibitors; Lopinavir; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Antirheumatic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Indoles; Lopinavir; Medicine, Chinese Traditional; Ritonavir; SARS-CoV-2; Treatment Outcome | 2021 |
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication | 2021 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Indoles; Interferon beta-1a; Lopinavir; Male; Middle Aged; Ritonavir | 2021 |
Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Indoles; Lopinavir; Ritonavir; SARS-CoV-2; Sulfides; Treatment Outcome | 2022 |
4 trial(s) available for umifenovir and ritonavir
| Article | Year |
|---|---|
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Topics: Adult; COVID-19 Drug Treatment; Humans; Indoles; Lopinavir; Ritonavir; SARS-CoV-2; Sulfides | 2020 |
Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
Topics: Adult; Animals; Anti-Inflammatory Agents; Antiviral Agents; Coronavirus 229E, Human; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Lung; Male; Mice; Mice, Inbred BALB C; Middle Aged; Molecular Docking Simulation; NF-kappa B; Ritonavir; SARS-CoV-2; Signal Transduction; Viral Load | 2021 |
Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Case-Control Studies; China; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Indoles; Interleukin-17; Lopinavir; Middle Aged; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Th17 Cells; Treatment Outcome | 2020 |
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Ritonavir; SARS-CoV-2 | 2020 |
20 other study(ies) available for umifenovir and ritonavir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Topics: Adult; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2020 |
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Topics: Administration, Oral; Adult; Antiviral Agents; Cohort Studies; Coronavirus Infections; COVID-19; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Tomography, X-Ray Computed | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Topics: Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Quadruple therapy for asymptomatic COVID-19 infection patients.
Topics: Asymptomatic Infections; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Topics: Adult; Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Lopinavir; Male; Ritonavir; SARS-CoV-2 | 2020 |
Treatment strategies of hospitalized patients with coronavirus disease-19.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Female; gamma-Globulins; Glucocorticoids; Hospitalization; Humans; Immunologic Factors; Indoles; Interferons; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Indoles; Interferon-alpha; Lopinavir; Lung; Male; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Ritonavir; SARS-CoV-2; Sputum; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; China; Cohort Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospital Mortality; Host Microbial Interactions; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Treatment Outcome; Young Adult | 2020 |
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2 | 2020 |
A retrospective comparison of drugs against COVID-19.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Viral; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunoglobulin G; Immunoglobulin M; Indoles; Length of Stay; Lopinavir; Male; Middle Aged; Oseltamivir; Retrospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2021 |
Can we use hydroxychloroquine to treat COVID-19 now?
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Indoles; Interferon-alpha; Lopinavir; Ritonavir; SARS-CoV-2; Uncertainty | 2021 |
Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
Topics: Antiviral Agents; China; COVID-19 Drug Treatment; Drug Combinations; Female; Fever; Humans; Indoles; Length of Stay; Lopinavir; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2021 |
Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study.
Topics: Anti-Bacterial Agents; Antiviral Agents; China; COVID-19 Drug Treatment; Female; Glucocorticoids; Humans; Immunologic Factors; Indoles; Linezolid; Lopinavir; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Ritonavir | 2021 |
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Humans; Indoles; Lopinavir; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2021 |
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Drug Treatment; Female; Humans; Indoles; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Electrocardiography; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Indoles; Interferons; Long QT Syndrome; Lopinavir; Male; Middle Aged; Odds Ratio; Quinolones; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |
Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
Topics: Animals; COVID-19 Drug Treatment; Drug Interactions; Drug Therapy, Combination; Female; Indoles; Lopinavir; Male; Rats; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2021 |